Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh look 2.20 ah yea
Oh look a shorter gasping for hope lol
Statement of Ownership (sc 13g)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Aytu BioScience, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
054754700
(CUSIP Number)
March 12, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
a. ? Rule 13d-1(b)
b. ? Rule 13d-1(c)
c. ? Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 1 of 9
CUSIP No. 054754700
1. Names of Reporting Persons.
Mitchell P. Kopin
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
3. SEC Use Only
4.
Citizenship or Place of Organization
United States of America
Number of
Shares Beneficially
Owned by Each
Reporting
Person With:
5.
Sole Voting Power
0
6.
Shared Voting Power
3,517,022
7.
Sole Dispositive Power
0
8.
Shared Dispositive Power
2,032,022
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
3,517,022 (see Item 4)
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
3.7% (see Item 4)
12. Type of Reporting Person (See Instructions)
IN; HC
Page 2 of 9
CUSIP No. 054754700
1. Names of Reporting Persons.
Daniel B. Asher
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
3. SEC Use Only
4.
Citizenship or Place of Organization
United States of America
Number of
Shares Beneficially
Owned by Each
Reporting
Person With:
5.
Sole Voting Power
0
6.
Shared Voting Power
3,517,022
7.
Sole Dispositive Power
0
8.
Shared Dispositive Power
2,032,022
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
3,517,022 (see Item 4)
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
3.7% (see Item 4)
12. Type of Reporting Person (See Instructions)
IN; HC
Page 3 of 9
CUSIP No. 054754700
1. Names of Reporting Persons.
Intracoastal Capital LLC
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
3. SEC Use Only
4.
Citizenship or Place of Organization
Delaware
Number of
Shares Beneficially
Owned by Each
Reporting
Person With:
5.
Sole Voting Power
0
6.
Shared Voting Power
3,517,022
7.
Sole Dispositive Power
0
8.
Shared Dispositive Power
2,032,022
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
3,517,022 (see Item 4)
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11.
Percent of Class Represented by Amount in Row (9)
3.7% (see Item 4)
12. Type of Reporting Person (See Instructions)
OO
Page 4 of 9
Item 1.
(a) Name of Issuer
Aytu BioScience, Inc. (the “Issuer”)
(b) Address of Issuer’s Principal Executive Offices
373 Inverness Parkway, Suite 206
Englewood, CO 80112
Item 2.
(a) Name of Person Filing
(b) Address of Principal Business Office or, if none, Residence
(c) Citizenship
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).
The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.
The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.
(d) Title of Class of Securities
Common Stock, $0.0001 par value per share, of the Issuer (the “Common Stock”).
(e) CUSIP Number
054754700
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Page 5 of 9
Item 4. Ownership.
(a) and (b):
(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on March 12, 2020 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on March 13, 2020), each of the Reporting Persons may have been deemed to have beneficial ownership of 4,000,000 shares of Common Stock, which consisted of (i) 2,000,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 2,000,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 8.7% of the Common Stock, based on (1) 42,181,436 shares of Common Stock outstanding as of March 11, 2020 as reported by the Issuer, plus (2) 2,000,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 2,000,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 89,500 shares of Common Stock issuable upon an exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 22,220 shares of Common Stock issuable upon an exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 25,397 shares of Common Stock issuable upon an exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 2,381 shares of Common Stock issuable upon an exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, and (V) 125 shares of Common Stock issuable upon an exercise of a fifth warrant held by Intracoastal (“Intracoastal Warrant 6”) because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 4,139,623 shares of Common Stock.
(ii) As of the close of business on March 23, 2020, each of the Reporting Persons may have been deemed to have beneficial ownership of 3,517,022 shares of Common Stock, which consisted of (i) 1,485,000shares of Common Stock held by Intracoastal, (ii) 325,000shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (iii) 1,567,399 shares of Common Stock issuable upon exercise of a sixth warrant held by Intracoastal (“Intracoastal Warrant 7”), (iv) 89,500 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 2, (v) 22,220 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 3, (vi) 25,397 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 4, (vii) 2,381 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 5, and (viii) 125 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 6, and all such shares of Common Stock represented beneficial ownership of approximately 3.7% of the Common Stock, based on (1) 90,952,162 shares of Common Stock outstanding immediately following the closing of the transaction disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on March 20, 2020, as reported by the Issuer, plus (2) 200,000 shares of Common Stock issued in the aggregate upon exercise of Intracoastal Warrant 1, (3) 325,000shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (4) 1,567,399 shares of Common Stock issuable upon exercise of Intracoastal Warrant 7, (5) 89,500 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 2, (6) 22,220 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 3, (7) 25,397 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 4, (8) 2,381 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 5, (9) 125 shares of Common Stock issuable upon an exercise of Intracoastal Warrant 6 and (10) 1,475,000 shares of Common Stock issued or to be issued upon an exercise by Intracoastal of Intracoastal Warrant 1.
(c) Number of shares as to which each Reporting Person has:
(i) Sole power to vote or to direct the vote: 0 .
(ii) Shared power to vote or to direct the vote: 3,517,022 .
(iii) Sole power to dispose or to direct the disposition of 0 .
(iv) Shared power to dispose or to direct the disposition of 2,032,022 .
Page 6 of 9
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ?.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
Page 7 of 9
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: March 23, 2020
/s/ Mitchell P. Kopin
Mitchell P. Kopin
/s/ Daniel B. Asher
Daniel B. Asher
Intracoastal Capital LLC
By: /s/ Mitchell P. Kopin
Mitchell P. Kopin, Manager
Page 8 of 9
Exhibit 1
JOINT FILING AGREEMENT
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Date: March 23, 2020
/s/ Mitchell P. Kopin
Mitchell P. Kopin
/s/ Daniel B. Asher
Daniel B. Asher
Intracoastal Capital LLC
By: /s/ Mitchell P. Kopin
Mitchell P. Kopin, Manager
Page 9 of 9
Come on 2.20
Yea crayons is here
Denver is on lock down starting tomorrow at 5pm
Hang on here we go
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2020
AYTU BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38247
47-0883144
(State or other jurisdictionof incorporation)
(Commission File Number)
(IRS Employer Identification No.)
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (720) 437-6580
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
AYTU
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 8.01 Other Events
On March 23, 2020, Aytu BioScience, Inc. (the “Company"), reported that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 (“COVID-2019”) IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.
In addition, the Company expects delivery of its first shipment of 100,000 tests this week. The Company has been in discussions with healthcare distributors, healthcare institutions, medical practices, and government agencies and is working quickly to begin distribution into the U.S. healthcare supply chain.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is being filed herewith:
Exhibit
Description
99.1
Press Release dated March 23, 2020
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AYTU BIOSCIENCE, INC.
Date: March 23, 2020
By:
/s/ Joshua R. Disbrow
Joshua R. Disbrow
Chief Executive Officer
Desperate shorts lol
Link please
I would not trust the reported #s from China about 0 cases of new infections
There are reports that people can get re-infected again. Scientists are looking into these re infected cases coming out of China
Thanks I know we are on the news here in Colorado if this his National this will explode
Link please
This news was again on channel 2 Fox News in Colorado tonight
News Data pix.
Rapid COVID-19 tests expected in Colorado next week
COVID-19 test kits that can produce results in anywhere from two to 10 minutes are expected to arrive at the Denver International Airport early next week, Rob Low reports.
v
DENVER
Any one know about Aytu warrants bought a small chunk. Have never played with warrants. How do they work.
We need news from the company
Link please
Link please
Test kits not shares
Then will get more and sell more wash rinse and repeat! See how that works both ways!
Yea the shorts are going to be attacking this hard now. Shipment has arrived. Will be going to Colorado based Aytu. Governor Polis has already announced on camera he would take all 100,000.00 kits
I posted that link to the video this morning and last night. Bye bye SHORTS!
No the date says 3/18/2020 need to get your eyes checked
Wrong board sorry
Aytu in the news
Just a matter of time
Check out the link 1:23 min into video
This was posted on Aytuz board
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2020
AYTU BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-38247
47-0883144
(State or other jurisdictionof incorporation)
(Commission File Number)
(IRS Employer Identification No.)
373 Inverness Parkway, Suite 206
Englewood, CO 80112
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (720) 437-6580
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
AYTU
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 8.01 Other Events
On March 13, 2020, Aytu BioScience, Inc. (the “Company"), signed an Addendum to a distribution agreement previously signed March 9, 2020 (the “Addendum”) for the right to commercialize a clinically validated and commercially used coronavirus 2019 (COVID-19) IgG/IgM Rapid Test. The test has been licensed from L.B. Resources, Limited (a Hong Kong Corporation). The test is intended for professional use and delivers clinical results between 2 and 10 minutes at the point-of-care. This Addendum grants Aytu the additional rights to distribute the product in both Canada and Mexico for a period of three years, with additional three-year autorenewals thereafter. The Company expects to pursue expedited regulatory clearance of the product with Health Canada and COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the regulatory agencies in Canada and Mexico, respectively.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AYTU BIOSCIENCE, INC.
Date: March 19, 2020
By:
/s/ Joshua R. Disbrow
Joshua R. Disbrow
Chief Executive Officer
https://apple.news/A8CXG7T0_RGKCh3TTDXN_yg
Washington Post talks about lack of testing in Colorado
With all the news about lack of testing kits you would think this would fly. Been on local news twice Governor of Colorado said on TV that he would take all 100,000,00 test kits from Aytu. ?????
Need that link sticked
Going to repost this link in the am
How do we get that link sticked
This is not a political chat room men. Let’s keep politics out of this please.